Business Context and Reporting Period
Company: Akers Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 31, 2018
Reporting Period: Event date October 31, 2018
Context: The Company, an emerging growth company incorporated in New Jersey, entered into a Material Definitive Agreement to raise capital through a private placement of equity securities.
Key Financial Metrics and Transaction Details
Transaction Overview:
- Securities Issued: 5,555,556 shares of common stock and warrants to purchase approximately 5,555,556 shares of common stock.
- Combined Purchase Price: $0.36 per unit (one share of common stock plus one warrant).
- Warrant Exercise Price: $0.47 per share.
- Warrant Terms: Immediately exercisable; expire five years from the date of issuance.
- Ownership Limitation: Beneficial ownership limited to 4.99% of outstanding shares immediately after exercise (subject to limited exceptions).
Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It reports a specific financing event rather than periodic financial performance.
Material Changes Versus Prior Period
This filing reports a discrete capital raise event and does not contain comparative financial data or year-over-year operational changes. The primary material change is the increase in authorized and outstanding equity resulting from the issuance of 5,555,556 new shares and associated warrants.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations beyond the terms of the securities purchase agreement.
Risks and Contingencies:
- Dilution: The issuance of new shares and warrants will result in dilution to existing shareholders.
- Adjustments: Warrant exercise prices and share counts are subject to adjustment for stock splits, dividends, combinations, and rights offerings.
- Fundamental Transactions: In the event of a merger or acquisition, warrant holders have the option to receive equivalent securities in the successor entity or the same consideration as common stockholders.
Investor Verification Checklist
- Verify the total gross proceeds raised by calculating 5,555,556 units multiplied by the $0.36 purchase price.
- Confirm the impact of the 4.99% beneficial ownership limitation on the ability of investors to exercise warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Form of Warrant (Exhibit 4.1) for specific covenants and redemption rights not detailed in the summary.
- Check subsequent filings to confirm the closing of the offering and the actual number of shares issued.